Linden Thomas Advisory Services LLC Has $1.26 Million Holdings in Insulet Co. (NASDAQ:PODD)

Linden Thomas Advisory Services LLC boosted its holdings in Insulet Co. (NASDAQ:PODD) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,817 shares of the medical instruments supplier’s stock after buying an additional 73 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Insulet were worth $1,262,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PODD. Parkside Financial Bank & Trust boosted its stake in Insulet by 251.0% in the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Wolff Wiese Magana LLC boosted its stake in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Insulet during the third quarter valued at about $31,000. Finally, Lindbrook Capital LLC boosted its stake in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PODD shares. Piper Sandler cut their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Barclays cut their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Stifel Nicolaus lifted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Finally, JPMorgan Chase & Co. lifted their price target on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $243.21.

Insider Activity

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.90% of the company’s stock.

Insulet Trading Down 0.0 %

Shares of PODD stock opened at $167.25 on Thursday. The company has a market cap of $11.71 billion, a P/E ratio of 57.47, a PEG ratio of 3.01 and a beta of 0.98. The stock has a 50 day simple moving average of $172.53 and a two-hundred day simple moving average of $179.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 earnings per share. Research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.